Ephynal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ephynal

Property Description
Active ingredient Alpha-tocopherol acetate (Tocopherol acetate)
Form Capsule (Softgel), Tablet, Solution for injection
Pharmacological class Vitamin E Preparation / Nutritional Supplement
General purpose Prevention and correction of Vitamin E deficiency
Origin Semi-synthetic (Ester derivative), Fat-soluble

Identity: Classification as a Fat-Soluble Vitamin Preparation

Ephynal is a pharmaceutical preparation and a Nutritional Supplement intended to supply the essential fat-soluble nutrient, alpha-tocopherol, in a stable form. Its primary role, clinically recognized across global health organizations, is to address or prevent a Vitamin E deficiency. Pharmacologically, its active ingredient, Tocopherol acetate, is classified by the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system under A11HA03 (Other plain vitamin preparations). The preparation is fundamentally defined by its composition: the International Nonproprietary Name (INN) of the active agent is Tocopherol acetate. As a fat-soluble vitamin derivative, it is available for both oral intake, often in capsules utilizing a fatty oil base, and for intramuscular (IM) injection.


The Composition: A Stable, Fat-Soluble Antioxidant

The active ingredient, Alpha-tocopherol acetate, is an ester created by chemically linking the alpha-tocopherol molecule with an acetate group. This modification produces a stabilized precursor or prodrug that protects the vitamin from chemical degradation, ensuring a reliable delivery system. The alpha-tocopherol form is the only one biologically recognized to meet human requirements. The key physiological action of the regenerated alpha-tocopherol molecule is that of a powerful antioxidant, which works to protect crucial cell membranes from damage caused by unstable free radicals. This protective mechanism underpins its general benefit in supporting the body's natural processes related to cell health and metabolism.

Regulatory References

  1. Vitamin E and deficiency (WHO)

What side effects are possible with Ephynal?

Possible side effects and safety information

The official safety profile for Ephynal (Alpha-tocopherol acetate) primarily documents adverse reactions linked to the consumption of doses significantly higher than standard nutritional requirements. The risk profile is heavily dose-dependent, meaning effects are most often observed when usage exceeds established upper limits.


Documented Adverse Reactions

Adverse effects listed in regulatory documents are generally organized by the physiological system affected (System-Organ Class).

  • Gastrointestinal Disturbances: Reactions such as diarrhea and abdominal pain are associated with very high doses, specifically those exceeding 1 gram daily. These effects are considered transient.
  • Rare Systemic Effects: At dosages exceeding 300 IU daily, effects such as headache, fatigue, nausea, and rash have been documented, generally classified as rare in official safety data. These effects are typically reversible upon discontinuation.

Serious Safety Considerations and Constraints

Specific serious adverse reactions and safety constraints are explicitly documented in regulatory materials, particularly those related to the blood and circulation systems.

Category Safety Statement (Regulatory Basis)
Bleeding Risk High-dose use, especially over prolonged periods, carries a documented risk of increased bleeding tendency (haemorrhage). This risk is amplified in patients with Vitamin K deficiency or those concurrently taking anticoagulant medicines.
Thrombosis Risk The possibility of an increased risk of thrombosis (blood clot formation) must be considered, particularly in patients who are simultaneously taking estrogen-containing medicines.
Pediatric Constraint A higher incidence of necrotising enterocolitis (a severe bowel condition) has been noted in the safety profile for very low-weight premature infants (less than 1.5 kg) following high-dose administration.

These constraints establish that the medicine's safety profile requires specific caution in individuals with pre-existing coagulation issues or those on interacting treatments.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Alpha-tocopherol acetate (Ephynal) overdose establishes that toxicity is primarily linked to chronic, high-dose exposure, typically sustained at 1000 mg or more daily. Acute toxicity is generally considered low in regulatory classifications.

Documented Overdose Manifestations

Overdose may present with common, transient symptoms affecting the gastrointestinal system, including diarrhea, abdominal pain, and nausea. Systemic effects such as fatigue, weakness, headache, and blurred vision are also documented with long-term, excessive intake.

Life-Threatening Outcomes and Required Action

The most significant outcome documented by regulatory sources is an increased risk of bleeding or hemorrhage, which is linked to the vitamin's ability to interfere with the body's Vitamin K metabolism. This risk elevates the overdose severity classification.

In the event of severe manifestations, particularly any signs of bleeding or hemorrhage, immediate medical attention must be sought. Official response statements mandate the withdrawal of the product and the provision of symptomatic and supportive treatment. No specific antidote is known to be available.

Population-Specific Considerations

Patients concurrently receiving oral anticoagulants (e.g., Warfarin) are identified in regulatory labeling as a population with increased risk. Coagulation status requires close monitoring in these individuals during high-dose exposure to address the documented risk.

Therapeutic Uses of Ephynal

Ephynal is commonly used to help with a nutritional need, primarily by addressing vitamin E deficiency. This therapeutic support is applied across domains where additional symptomatic support is needed. Deficiency is considered relevant in contexts involving heightened systemic burden and is applicable in conditions involving episodic or fluctuating manifestations where functional stability becomes affected.

This medicine plays a role in managing symptoms related to systemic imbalance. Clinical scenarios often involve phases when symptoms become more noticeable, and supportive relief is needed. This use contributes to easing the overall symptom load and supports the patient during episodes of heightened discomfort. It assists with maintaining functional stability. This benefit is relevant when supportive symptom management is appropriate and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Applied in addressing symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information on Vitamin E

Eligibility and Restrictions for Use

Ephynal (dl-alpha-tocopherol acetate, a form of Vitamin E) is a medicine whose eligibility is defined by both the patient's condition and the ingredients in the injectable form.

Official Eligibility and Restrictions

Classification Populations and Conditions
Contraindicated Individuals with known hypersensitivity (severe allergy) to the active substance (alpha-tocopherol acetate) or to any excipient, such as Polyoxyl 35 Hydrogenated Castor Oil (also known as CREMOPHOR EL).
Restricted Use Patients concurrently taking Antivitamin K oral anticoagulants (blood thinners) must use this medicine with caution. This combination increases the risk of haemorrhage and requires frequent monitoring of prothrombin levels and INR.
Allowed Use Adults and the paediatric population are eligible for use to address Vitamin E deficiency or digestive malabsorption when oral intake is insufficient. Use in pregnancy and lactation is permitted if deemed medically necessary.
Administration Restriction The injectable solution must be given via deep intramuscular injection only. It is prohibited for subcutaneous injection due to the risk of severe reactions associated with the excipient.

Eligibility for this medicine is based on addressing a diagnosed deficiency, with key constraints tied to a patient's allergic profile, concomitant use of blood-thinning medication, and a strict requirement for the correct route of administration.

What should I know about interactions with other medicines?

The interaction profile for Ephynal (Alpha-tocopherol acetate) is primarily structured around two classes of documented interaction risks: pharmacodynamic potentiation and pharmacokinetic interference.

Interactions with Antithrombotic Agents

High daily doses, such as those exceeding 1000 mg or 1490 IU, may potentiate the effects of anticoagulants (e.g., Warfarin) and antiplatelet agents. This pharmacodynamic interaction is officially documented as raising the risk of haemorrhage (bleeding). Co-administration with Estrogens is also noted in regulatory documents as potentially increasing the risk of thrombosis. Additionally, Ephynal may enhance the side effects of specific medicines, including Amiodarone, Ciclosporin, and Zidovudine.

Absorption Interference and Timing Rules

Due to its fat-soluble nature, Ephynal's absorption may be compromised by agents that interfere with fat processing. Orlistat, a lipase inhibitor, and Bile Acid Sequestrants (e.g., Colestyramine) both officially reduce Vitamin E absorption. The interaction profile establishes mandatory timing rules for these agents: administration with Orlistat must be separated by two hours, and separation from Bile Acid Sequestrants requires taking Ephynal at least 1 to 2 hours before or 4 to 6 hours after the sequestrant. Other medicines, including Anticonvulsants (e.g., Phenytoin) and Oral Contraceptives, are documented to lower the plasma levels of Vitamin E.

Herbal Products and Specific Considerations

High doses may also potentiate the effects of herbal products with antithrombotic activity, such as Garlic and Ginkgo. A specific note exists regarding its effect on Iron Preparations: dosages above 4.5 mg/kg daily may delay the response to iron therapy in children with iron-deficiency anaemia.

Mechanism of Action

Chain-Breaking Lipid Antioxidant Mechanism

The mechanism initiates when active alpha-tocopherol incorporates into the cell's lipid bilayers. It acts as a chain-breaking lipid antioxidant by neutralizing highly reactive Lipid Peroxyl Radicals ( ROOcdot) through hydrogen atom donation . This action is essential for terminating the destructive lipid peroxidation cascade, which otherwise leads to widespread degradation of the Polyunsaturated Fatty Acids (PUFAs) within membranes.


Membrane Stabilization and Structural Integrity

The consequence of this antioxidant mechanism is the maintenance of cell membrane integrity and the physical stability of cells, particularly in structures like erythrocytes and neuronal tissue. This mechanism ensures the physical stability and functional capacity of these cells, preventing breakdown processes like hemolysis in red blood cells. Furthermore, alpha-tocopherol engages in non-antioxidant modulation, influencing enzyme activity like Protein Kinase C (PKC) and modulating the expression of adhesion molecules, which influences dynamics within the vascular pathway.

Dosage and Administration Information

How to use Ephynal: Official Administration Guidelines

Ephynal is for oral administration and is indicated for use in ambulatory patients aged 5 years and older. The total daily dose is 40 mg/kg total body weight, divided into three separate doses over the course of the day. The dose must be prepared immediately before use by mixing the full contents of the sachet(s) into a suspension.

Official Dosing and Preparation

The full contents of the prescribed sachet(s) must be mixed with at least 30 ml of liquid (such as water, milk, or fruit juice) or three tablespoons of semi-solid food (such as yogurt or apple sauce). The mixture must be well-mixed until a uniform suspension is formed and then administered. The administration must follow a three times daily (TID) frequency pattern:

Dosing Timing Dose Proportion Minimum Interval to Next Dose
Morning 10 mg/kg body weight 6 hours (to Midday dose)
Midday 10 mg/kg body weight 6 hours (to Evening dose)
Evening 20 mg/kg body weight 12 hours (to Morning dose)

Missed Dose Instructions

If the administration of a dose is delayed, specific instructions must be followed to maintain the correct regimen. If the delay is less than 3 hours for the morning or midday doses, or less than 6 hours for the evening dose, the missed dose should be taken. If the delay is more than these timeframes, the dose should be skipped, and the patient should resume the usual dosing schedule. Do not take a double or extra dose to compensate for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ephynal


Evidence for Confirmed Vitamin E Deficiency

Ephynal (Alpha-tocopherol Acetate) was studied for its potential to achieve biochemical correction and for tracking neurological symptoms, which is the medicine's primary recognized purpose. Research in this area often relies on historical observational case series and small, older interventional trials because the severe form of deficiency, particularly that caused by certain genetic conditions like AVED (Ataxia with Vitamin E Deficiency), is rare.

These studies examined patients with confirmed low blood levels of alpha-tocopherol due to malabsorption conditions or genetic defects. The research monitored outcomes such as the achievement of normal Vitamin E levels in the blood (biochemical correction) and the tracking of neurological symptoms (like issues with coordination or peripheral nerve function), which are characteristic of the deficiency.


Evidence for Conditions Causing Secondary Deficiency (Cystic Fibrosis and Malabsorption)

Research has explored the use of Ephynal in populations that face a high risk of developing a deficiency because of an underlying medical condition, such as Cystic Fibrosis (CF). The evidence for CF includes Randomized Controlled Trials (RCTs) and systematic reviews that were studied for their impact on nutritional status.

Trial data showed patterns related to the maintenance of Vitamin E levels within normal ranges for people with CF who used the supplement. However, the findings were mixed regarding whether this biochemical maintenance directly influenced major long-term clinical outcomes for CF, such as changes in lung function or growth. Evidence quality varies across studies due to differences in design and reporting, and the follow-up durations were modest in the intervention phase.


Strength of Evidence and Current Research Gaps

For the correction of established Vitamin E deficiency, the evidence, though often historical and based on modest sample sizes, describes similar patterns regarding biochemical effects and findings monitored the evolution of symptoms.

For the more general indication of supportive symptom management in non-specific contexts, research remains descriptive and observational, not derived from rigorous, large-scale interventional trials. Therefore, the certainty remains low for these broad, non-specific applications. The results apply only to the populations studied, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Ephynal (FAQ)


Q: Is it necessary to take Ephynal with food?

A: According to the official product information, Ephynal is a fat-soluble derivative. The administration guidelines for the sachet formulation describe that the contents are to be mixed with liquid (such as water or milk) or a semi-solid food (like yogurt or applesauce) to form a uniform suspension. This preparation method is described in the official product information.

Q: What kind of stomach issues are associated with Ephynal?

A: Regulatory safety documents state that very high doses of Ephynal may be associated with gastrointestinal disturbances. The specific effects documented in official reports include diarrhea and abdominal pain. These effects are generally considered transient and may resolve upon stopping the medicine.

Q: Can Ephynal be taken by children?

A: Official administration guidelines state that Ephynal is indicated for use in ambulatory patients aged 5 years and older. The paediatric population is generally eligible to use the medicine to address a diagnosed Vitamin E deficiency or digestive malabsorption issues.

Q: Is Ephynal safe for older adults (seniors)?

A: Official documents describe that the medicine is indicated for use in the adult population to address Vitamin E deficiency. The official safety constraints and restrictions listed in regulatory documents do not specify unique risks or contraindications that are specific only to the general older adult population.

Q: Are there any common supplements or vitamins that interact with Ephynal?

A: The official interaction profile notes that high doses of Ephynal may enhance the effects of certain herbal products with antithrombotic (blood-thinning) activity, such as Garlic and Ginkgo. Additionally, in children with iron-deficiency anaemia, dosages above a certain daily threshold may delay the response to iron therapy.

Q: What official government research has been done on Ephynal?

A: The evidence base for Ephynal includes various studies such as historical observational case series, small, older interventional trials, and Randomized Controlled Trials (RCTs). This research has examined the medicine's ability to achieve biochemical correction and its influence on neurological symptoms associated with deficiency, especially in conditions like Cystic Fibrosis.

Q: Is Ephynal used for long-term or short-term treatment?

A: Official safety warnings indicate a potential increased risk of bleeding tendency linked to high-dose use over prolonged periods. Research has also explored the use of the medicine for managing chronic conditions, such as Cystic Fibrosis, suggesting a role in long-term maintenance of vitamin levels.

Q: Can Ephynal be crushed or split if a person has trouble swallowing?

A: For the sachet formulation, administration rules require mixing the full contents into a liquid or semi-solid food to create a uniform suspension. However, the regulatory documents do not provide instruction for crushing or splitting other available forms of the medicine, such as the capsules or tablets.

Q: What information should I give my doctor before starting Ephynal?

A: Regulatory documents outline specific health information that establishes constraints for use. This includes any known severe allergy (hypersensitivity) to the drug or its excipients, as well as if one is concurrently taking Antivitamin K oral anticoagulants or estrogen-containing medicines.

Q: Does Ephynal have any warnings related to driving or operating machinery?

A: The official safety data documents that side effects such as fatigue and headache are rare and reversible at higher doses. However, the regulatory text does not contain an explicit warning regarding the safe operation of vehicles or heavy machinery.

Q: Is Ephynal a type of antibiotic or something else?

A: Ephynal is not an antibiotic. It is officially classified as a Vitamin E Preparation and a Nutritional Supplement. Its active ingredient is a fat-soluble nutrient derivative called alpha-tocopherol acetate.

Q: Why do some people refer to Ephynal as a 'preventative' medicine?

A: The general purpose of Ephynal, which is recognized across global health organizations, is the prevention and correction of Vitamin E deficiency. Its use in high-risk populations aims to prevent the development of a deficiency due to underlying medical conditions.

Q: Do the side effects of Ephynal usually go away after a few days?

A: Official safety documents indicate that adverse effects are generally considered transient. For example, documented effects like headache, fatigue, nausea, and rash are typically reversible once the patient stops taking the medicine.

Q: Is it normal to feel tired or dizzy when first starting Ephynal?

A: Fatigue is documented as a rare, reversible side effect associated with dosages exceeding 300 IU daily. Dizziness is not explicitly listed among the documented rare systemic effects in the provided regulatory text.

Q: What are the official recommendations for using Ephynal during pregnancy?

A: According to the official eligibility criteria, use of Ephynal during pregnancy is permitted if it is deemed medically necessary.

Q: Is Ephynal safe to use while breastfeeding?

A: Official eligibility criteria state that the use of Ephynal during lactation (breastfeeding) is permitted if it is deemed medically necessary.

Q: Is Ephynal available generically, or only as a brand name?

A: Ephynal is the proprietary (brand) name. The active substance is alpha-tocopherol acetate, which is the International Nonproprietary Name (INN) of the agent. Medicines may be available under their INN once exclusivity periods expire.

Q: What is the difference between the various strengths of Ephynal available?

A: Ephynal is available in several forms, including capsules, tablets, and a solution for injection. While the official administration guidelines define the total daily dose based on body weight, the specific milligram or International Unit strengths of the different forms are not detailed in this section.

Q: Are there specific food groups or diet restrictions while on Ephynal?

A: Regulatory documents do not list restrictions on specific food groups or broad dietary requirements. The interaction profile notes a potential interaction if consuming herbal products, such as Garlic and Ginkgo, that have antithrombotic effects.

Q: Can Ephynal be taken if I am scheduled for surgery?

A: Regulatory documents establish constraints for use in individuals with pre-existing coagulation issues or those concurrently taking anticoagulants. This is due to a documented risk of increased bleeding tendency (haemorrhage) associated with high-dose use.

Q: Does Ephynal need to be stored in the refrigerator?

A: The official storage conditions require that Ephynal be stored at a temperature not exceeding 25°C (77°F). It must be protected from light, heat, and humidity, and kept in a tightly sealed, light-resistant container.

Q: Does Ephynal have any interactions with herbal teas or remedies?

A: The official interaction profile notes that high doses of Ephynal may potentiate the effects of certain herbal products. Specifically, the profile mentions herbal products with antithrombotic activity, such as Garlic and Ginkgo.

How should Ephynal be stored and disposed of?

Ephynal (alpha-tocopherol acetate) must be stored and disposed of according to strict regulatory requirements to maintain its stability and integrity.

Official Storage Conditions

The product must be stored at a temperature not exceeding 25°C (77°F). It is mandatory to protect the contents from light, heat, and humidity. Storage requires a tightly sealed, light-resistant container.

For the solution for injection, the product must be used immediately after the ampoule is opened due to stability limitations. All medicinal products must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired medicinal product must be discarded. Disposal must not empty into drains and should avoid release to the environment, in accordance with applicable local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ephynal found in:

A-Z Index: